The American Association for Cancer Research (AACR) has awarded the 15th AACR-Irving Weinstein Foundation Distinguished Lectureship to Jeffrey Bluestone, PhD
The AACR-Irving Weinstein Foundation Distinguished Lectureship was established in 2004 to acknowledge an individual whose outstanding personal innovation in science and whose position as a thought leader in fields relevant to cancer research has had, and continues to have, the potential to inspire creative thinking and new directions in cancer research. The recipient of this award is selected annually by the AACR President.
Bluestone is being recognized for his scientific contributions to the fields of molecular biology and immunology, specifically his work involving the characterization of CD28 and CTLA-4 function, and subsequent studies demonstrating the role of T cells in modulating autoimmunity and organ transplant rejection. Collectively, his research accomplishments have revolutionized the understanding of T-cell biology and have been essential to the development of countless studies dedicated to understanding the role of the immune system in cancer initiation and progression.
“Dr. Bluestone is a world-renowned researcher whose novel work on immunity has led to significant advances in the treatment of cancer and other diseases,” said Margaret Foti, PhD, Chief Executive officer of the AACR. “His work has helped us better understand autoimmunity, T-cell function, and immune system checkpoints. The AACR is thrilled to honor Dr. Bluestone and his groundbreaking work with this well-deserved lectureship.”